{"title": "Fase III de la vacuna inactivada COVID-19 de UNAIR (estudio de inmunopuente)", "author": null, "url": "https://ichgcp.net/es/clinical-trials-registry/NCT05508477", "hostname": "ichgcp.net", "description": "Este estudio es un ensayo cl\u00ednico de fase III, multic\u00e9ntrico, aleatorizado, doble ciego, controlado (Estudio de inmunopuente) para evaluar la inmunogenicidad y.... Registro de ensayos cl\u00ednicos. ICH GCP.", "sitename": "ichgcp.net", "date": "2022-08-18", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Fase III de la vacuna inactivada COVID-19 de UNAIR (estudio de inmunopuente)\n[Dr. Soetomo General Hospital](https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Dr.%20Soetomo%20General%20Hospital)\nUn ensayo cl\u00ednico de fase III, multic\u00e9ntrico, aleatorizado, doble ciego, controlado (estudio de inmunopuente) de Vaksin Merah Putih - UA SARS-CoV-2 (c\u00e9lulas Vero inactivadas) en poblaci\u00f3n sana de 18 a\u00f1os o m\u00e1s\nDescripci\u00f3n general del estudio\nEstado\nCondiciones\nDescripci\u00f3n detallada\nEste es un ensayo controlado aleatorizado doble ciego - estudio de inmunopuente. Habr\u00e1 2 grupos en el estudio. Un grupo de adultos (mayores de 18 a\u00f1os) con una dosis de 5 \u00b5g y un grupo de control con CoronaVac Bio Farma. Ambas vacunas se administrar\u00e1n con esquema de 2 dosis, por v\u00eda intramuscular. Todas las cohortes ser\u00e1n seguidas durante 6 meses.\nEste estudio tendr\u00e1 dos an\u00e1lisis intermedios y uno completo. El enfoque principal es la inmunogenicidad y los problemas de seguridad o reactogenicidad. La Junta de Monitoreo de Seguridad de Datos se encargar\u00e1 de este estudio para evaluar los datos de seguridad durante el per\u00edodo de estudio y revisar cualquier evento que cumpla con una regla espec\u00edfica de pausa del estudio o cualquier otro problema de seguridad que pueda surgir. Revisar\u00e1n los datos de seguridad ciegos a los 7 y 28 d\u00edas despu\u00e9s de la primera dosis de la vacuna, y luego a los 7 y 28 d\u00edas despu\u00e9s de la segunda dosis. Los datos de inmunogenicidad se evaluar\u00e1n hasta 6 meses despu\u00e9s de la segunda dosis\nTipo de estudio\nInscripci\u00f3n (Anticipado)\nFase\n- Fase 3\nContactos y Ubicaciones\nUbicaciones de estudio\n-\nIndonesia\n-\nEast Java\n-\nJember, East Java, Indonesia, 68111\n- Reclutamiento\n- Dr. Soebandi General Hospital\n-\nContacto:\n- Retna D Puspita, MD\n- N\u00famero de tel\u00e9fono: +62813-3118-0432\n-\nJember, East Java, Indonesia, 68118\n- Reclutamiento\n- Jember Paru Hospital\n-\nContacto:\n- Sigit K Jati, MD\n- N\u00famero de tel\u00e9fono: +6281233843628\n-\nMalang, East Java, Indonesia, 65112\n- Reclutamiento\n- Dr. Saiful Anwar General Hospital\n-\nContacto:\n- Cesarius S Wahono, MD\n- N\u00famero de tel\u00e9fono: +6281344110967\n-\nSurabaya, East Java, Indonesia, 67161\n- Reclutamiento\n- Dr. Soetomo General Hospital\n-\nSub-Investigador:\n- Yudi H Oktaviono, MD\n-\nSub-Investigador:\n- Deasy Fetarayani, MD\n-\nSurabaya, East Java, Indonesia, 60115\n- Reclutamiento\n- Airlangga University Hospital\n-\nContacto:\n- Brian E Rahman, MD\n- N\u00famero de tel\u00e9fono: +628123005886\n-\n-\nCriterios de participaci\u00f3n\nCriterio de elegibilidad\nEdades elegibles para estudiar\nAcepta Voluntarios Saludables\nG\u00e9neros elegibles para el estudio\nDescripci\u00f3n\nCriterios de inclusi\u00f3n:\n- Adultos sanos y ancianos, hombres y mujeres, mayores de 18 a\u00f1os. El investigador determinar\u00e1 el estado de salud en funci\u00f3n del historial m\u00e9dico, los resultados del laboratorio cl\u00ednico, las mediciones de los signos vitales y el examen f\u00edsico en el momento de la selecci\u00f3n.\n- Los sujetos han sido informados adecuadamente sobre el estudio y firmaron el formulario de consentimiento informado.\n- El sujeto se comprometer\u00e1 a cumplir con las instrucciones del investigador y el cronograma del ensayo.\n- Los participantes aceptan no donar m\u00e9dula \u00f3sea, sangre ni hemoderivados desde la primera administraci\u00f3n de la vacuna del estudio hasta 3 meses despu\u00e9s de recibir la \u00faltima dosis de la vacuna del estudio.\n- Los participantes deben estar dispuestos a proporcionar una identificaci\u00f3n verificable, tener medios para ser contactados y comunicarse con el investigador durante el estudio.\nCriterio de exclusi\u00f3n:\n- Sujetos inscritos concomitantemente o programados para ser inscritos en otro ensayo de vacuna.\n- Enfermedad leve, moderada y grave en evoluci\u00f3n, especialmente enfermedades infecciosas o fiebre (temperatura axilar de 37,5 grados cent\u00edgrados o m\u00e1s) concurrente o dentro de los 7 d\u00edas anteriores a la primera vacunaci\u00f3n del estudio. Esto incluye s\u00edntomas respiratorios o constitucionales compatibles con SARS-CoV-2 (tos, dolor de garganta, dificultad para respirar, etc.)\n- Historia conocida de alergia a cualquier componente de las vacunas.\n- Antecedentes de coagulopat\u00eda no controlada o trastornos sangu\u00edneos que contraindiquen la inyecci\u00f3n intramuscular.\n- Cualquier enfermedad/condici\u00f3n autoinmune o de inmunodeficiencia\n- Sujetos que hayan recibido en las 4 semanas anteriores un tratamiento que pueda alterar la respuesta inmunitaria (inmunoglobulina intravenosa, productos derivados de la sangre, corticosteroides a largo plazo - m\u00e1s de 2 semanas, etc.), O anticipaci\u00f3n de la necesidad de tratamiento inmunosupresor dentro de los 6 meses despu\u00e9s de la \u00faltima vacunaci\u00f3n. Se permitir\u00e1 el uso de esteroides t\u00f3picos o nasales.\n- Enfermedad cr\u00f3nica inestable, incluida la hipertensi\u00f3n no controlada, insuficiencia card\u00edaca congestiva, enfermedad pulmonar obstructiva cr\u00f3nica, asma, urticaria cr\u00f3nica, diabetes que requiera el uso de medicamentos. La decisi\u00f3n final con respecto a esta condici\u00f3n la tomar\u00e1n los m\u00e9dicos de campo o el investigador a cargo.\n- Cualquier anormalidad o enfermedad cr\u00f3nica que, seg\u00fan el investigador, pueda interferir con la evaluaci\u00f3n de los objetivos del ensayo.\n- Personas que hayan recibido previamente alguna vacuna contra el Covid-19.\n- Sujetos ya inmunizados con cualquier vacuna dentro de las 4 semanas previas y esperan recibir otras vacunas dentro de los 60 d\u00edas posteriores a la primera dosis.\n- Individuos que tengan un Covid-19 previamente comprobado en el per\u00edodo de 1 mes (para personas leves, moderadas o asintom\u00e1ticas) o 3 meses (para Covid-19 severo) antes del primer reclutamiento de este estudio, o en un contacto cercano en el \u00faltimos 14 d\u00edas con caso confirmado de Covid-19.\n- Prueba positiva para SARS-CoV-2 (prueba de ant\u00edgeno o, si es necesario, prueba de PCR) en la detecci\u00f3n previa a la primera vacunaci\u00f3n. Las pruebas pueden repetirse durante el per\u00edodo de selecci\u00f3n si se sospecha la exposici\u00f3n a un caso positivo confirmado de SARS-CoV-2, a discreci\u00f3n del investigador.\n- Abuso de alcohol o sustancias\n- pacientes con VIH.\n- Pacientes con neoplasias malignas en los 2 a\u00f1os anteriores a la primera vacunaci\u00f3n del estudio.\n- Cualquier enfermedad neurol\u00f3gica o antecedentes de trastornos neurol\u00f3gicos significativos como meningitis, encefalitis, s\u00edndrome de Guillain-Barr\u00e9, esclerosis m\u00faltiple, etc.\n- Anomal\u00edas de signos vitales y anomal\u00edas de laboratorio cl\u00ednico seg\u00fan lo decidido por los investigadores. Las mediciones de los signos vitales y las pruebas de laboratorio cl\u00ednico pueden repetirse antes de la decisi\u00f3n final.\n- Mujeres que est\u00e1n embarazadas o que planean quedar embarazadas durante el estudio.\n- El participante tiene un problema o enfermedad psiqui\u00e1trica importante\n- El participante no puede comunicarse de manera confiable con el investigador\n- El participante tiene contraindicaciones para la inyecci\u00f3n intramuscular y las extracciones de sangre, como trastornos hemorr\u00e1gicos o fobia.\n- El participante se someti\u00f3 a una cirug\u00eda mayor dentro de las 12 semanas anteriores a la vacunaci\u00f3n que no se recuperar\u00e1 por completo, o tiene una cirug\u00eda mayor planificada durante el tiempo en que se espera que el participante participe en el estudio o dentro de los 6 meses posteriores a la \u00faltima dosis de la administraci\u00f3n de la vacuna del estudio.\n- Cualquier condici\u00f3n que, en opini\u00f3n de los investigadores, representar\u00eda un riesgo para la salud del sujeto si se inscribiera o podr\u00eda interferir con la evaluaci\u00f3n de la vacuna o la interpretaci\u00f3n de los resultados del estudio.\n- Miembros del equipo de estudio.\n- Sujeto que planea mudarse del \u00e1rea de estudio antes del final del per\u00edodo de estudio.\nPlan de estudios\n\u00bfC\u00f3mo est\u00e1 dise\u00f1ado el estudio?\nDetalles de dise\u00f1o\n- Prop\u00f3sito principal: PREVENCI\u00d3N\n- Asignaci\u00f3n: ALEATORIZADO\n- Modelo Intervencionista: PARALELO\n- Enmascaramiento: DOBLE\nArmas e Intervenciones\n|\n|\nGrupo de participantes/brazo\n|\n|\nIntervenci\u00f3n / Tratamiento\n|\n|\nEXPERIMENTAL: Vaksin Merah Putih - UA SARS-CoV-2 (c\u00e9lulas Vero inactivadas) 5 \u00b5g\nEl producto del estudio se proporciona en forma de l\u00edquido en vial de dosis \u00fanica (0,5 ml). La vacuna se administrar\u00e1 dos veces con un intervalo de 28 d\u00edas.\n|\n|\nVaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) contiene prote\u00edna S purificada de SARS-CoV-2 - Dosis: 5 \u00b5g, gel de hidr\u00f3xido de aluminio, tamp\u00f3n L-histidina 10 mM, 0,005%, Tween Polysorbate 80, y Cloruro de sodio al 0,9%. La vacuna se preparar\u00e1 en vial (1 ml por vial). Se utilizar\u00e1 un vial para una sola inyecci\u00f3n. El vial debe agitarse bien antes de la inyecci\u00f3n.\n|\n|\nCOMPARADOR_ACTIVO: Vacuna CoronaVac Biofarma COVID-19\nLa vacuna de control es la vacuna CoronaVac Bio Farma, suministrada por el Ministerio de Salud de Indonesia, en forma de vial de dos dosis. La vacuna se administrar\u00e1 dos veces con un intervalo de 28 d\u00edas.\n|\n|\nLa vacuna de control en este estudio es la vacuna COVID-19 inactivada CoronaVac-BioFarma existente que se ha utilizado ampliamente en Indonesia\n\u00bfQu\u00e9 mide el estudio?\nMedidas de resultado primarias\n|\n|\nMedida de resultado\n|\n|\nMedida Descripci\u00f3n\n|\n|\nPeriodo de tiempo\n|\n|\nEl perfil de inmunogenicidad humoral\nPeriodo de tiempo: 28 d\u00edas despu\u00e9s de la segunda vacunaci\u00f3n\n|\n|\nEl nivel de anticuerpos neutralizantes y no neutralizantes del SARS-CoV-2 entre los participantes\n|\n|\n28 d\u00edas despu\u00e9s de la segunda vacunaci\u00f3n\nMedidas de resultado secundarias\n|\n|\nMedida de resultado\n|\n|\nMedida Descripci\u00f3n\n|\n|\nPeriodo de tiempo\n|\n|\nEl perfil de seguridad\nPeriodo de tiempo: Dentro de los 30 minutos, 24 horas, 7 y 28 d\u00edas despu\u00e9s de cada dosis y 3 y 6 meses despu\u00e9s de la segunda dosis de vacunaci\u00f3n\n|\n|\nEvaluar el n\u00famero de eventos adversos que ocurren entre los participantes\n|\n|\nDentro de los 30 minutos, 24 horas, 7 y 28 d\u00edas despu\u00e9s de cada dosis y 3 y 6 meses despu\u00e9s de la segunda dosis de vacunaci\u00f3n\n|\n|\nEl perfil de inmunogenicidad humoral\nPeriodo de tiempo: 3 y 6 meses despu\u00e9s de la segunda vacunaci\u00f3n\n|\n|\nEl nivel de anticuerpos neutralizantes y no neutralizantes del SARS-CoV-2 entre los participantes\n|\n|\n3 y 6 meses despu\u00e9s de la segunda vacunaci\u00f3n\n|\n|\nEl perfil de inmunogenicidad celular\nPeriodo de tiempo: 3 y 6 meses despu\u00e9s de la segunda vacunaci\u00f3n\n|\n|\nEval\u00fae las respuestas inmunitarias Th1 y Th2, incluidos los CD4+/CD8+. IL-2, IL-4, TNF alfa, IFN gamma y otros marcadores despu\u00e9s de la estimulaci\u00f3n de PBMC con p\u00e9ptidos proteicos del SARS-CoV-2 y ensayo de liberaci\u00f3n de interfer\u00f3n gamma (IGRA) para evaluar la producci\u00f3n de IFN-\u03b3 a partir de CD4+ y CD8+ estimulados con p\u00e9ptidos antig\u00e9nicos espec\u00edficos del SARS-CoV-2 entre los participantes\n|\n|\n3 y 6 meses despu\u00e9s de la segunda vacunaci\u00f3n\nOtras medidas de resultado\n|\n|\nMedida de resultado\n|\n|\nMedida Descripci\u00f3n\n|\n|\nPeriodo de tiempo\n|\n|\nCoherencia lote a lote\nPeriodo de tiempo: 28 d\u00edas, 3 y 6 meses despu\u00e9s de la segunda inyecci\u00f3n para perfil de inmunogenicidad, y 30 minutos, 24 horas, 7 y 28 d\u00edas despu\u00e9s de cada vacunaci\u00f3n, y luego 3 y 6 meses despu\u00e9s de la segunda inyecci\u00f3n para aspectos de seguridad.\n|\n|\nLa comparaci\u00f3n de los aspectos de seguridad e inmunogenicidad (humoral y celular) entre los 3 lotes de vacunas utilizados en este ensayo\n|\n|\n28 d\u00edas, 3 y 6 meses despu\u00e9s de la segunda inyecci\u00f3n para perfil de inmunogenicidad, y 30 minutos, 24 horas, 7 y 28 d\u00edas despu\u00e9s de cada vacunaci\u00f3n, y luego 3 y 6 meses despu\u00e9s de la segunda inyecci\u00f3n para aspectos de seguridad.\nColaboradores e Investigadores\nPatrocinador\nPublicaciones y enlaces \u00fatiles\nPublicaciones Generales\n-\n[Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T; COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.](https://ichgcp.net/es/clinical-trials-registry/publications/5604-efficacy-and-safety-of-the-mrna-1273-sars-cov-2-vaccine)\n-\n[Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Perez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Tureci O, Nell H, Schaefer A, Unal S, Tresnan DB, Mather S, Dormitzer PR, Sahin U, Jansen KU, Gruber WC; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.](https://ichgcp.net/es/clinical-trials-registry/publications/5603-safety-and-efficacy-of-the-bnt162b2-mrna-covid-19-vaccine)\n-\n[Wang C, Wang Z, Wang G, Lau JY, Zhang K, Li W. COVID-19 in early 2021: current status and looking forward. Signal Transduct Target Ther. 2021 Mar 8;6(1):114. doi: 10.1038/s41392-021-00527-1.](https://ichgcp.net/es/clinical-trials-registry/publications/141516-covid-19-in-early-2021-current-status-and-looking-forward)\n-\n[Noh JY, Song JY, Yoon JG, Seong H, Cheong HJ, Kim WJ. Safe hospital preparedness in the era of COVID-19: The Swiss cheese model. Int J Infect Dis. 2020 Sep;98:294-296. doi: 10.1016/j.ijid.2020.06.094. Epub 2020 Jun 30.](https://ichgcp.net/es/clinical-trials-registry/publications/141517-safe-hospital-preparedness-in-the-era-of-covid-19-the-swiss-cheese-model)\n- New York Vaccine Tracker. Downloaded from https://www.nytimes.com/interactive/2020/science/coronavirus-vaccinetracker.html. Accessed 11 April 2022\n- Badan POM Republik Indonesia. Dowloaded from https://www.pom.go.id/new/view/more/pers/605/Pastikan-Keamanan-danMutu-Vaksin---Badan-POM-Kawal-Uji-Klinik-Vaksin-Merah-Putih.html. Accessed 11 October 2021.\n-\n[Irwin A. What it will take to vaccinate the world against COVID-19. Nature. 2021 Apr;592(7853):176-178. doi: 10.1038/d41586-021-00727-3. No abstract available.](https://pubmed.ncbi.nlm.nih.gov/33767468)\n-\n[So AD, Woo J. Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis. BMJ. 2020 Dec 15;371:m4750. doi: 10.1136/bmj.m4750.](https://ichgcp.net/es/clinical-trials-registry/publications/141518-reserving-coronavirus-disease-2019-vaccines-for-global-access-cross-sectional-analysis)\n- Worldometer coronavirus cases. Downloaded from https://www.worldometers.info/coronavirus/. Accessed 11 October 2021\n-\n[Biswas M, Rahaman S, Biswas TK, Haque Z, Ibrahim B. Association of Sex, Age, and Comorbidities with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis. Intervirology. 2020 Dec 9:1-12. doi: 10.1159/000512592. Online ahead of print.](https://ichgcp.net/es/clinical-trials-registry/publications/141519-association-of-sex-age-and-comorbidities-with-mortality-in-covid-19-patients-a-systematic-review-and)\n- Satuan Tugas Penanganan Covid-19. Downloaded from https://covid19.go.id/petasebaran. Accessed 11 October 2021\n- Cirrincione L, Plescia F, Ledda C, Rapisarda V, Martorana D, Moldovan RE, Theodoridou K, Cannizzaro E. COVID-19 Pandemic: Prevention and Protection Measures to Be Adopted at the Workplace. Sustainability 2020; 12: 3603\n- Bloomberg. Downloaded from https://www.bloomberg.com/graphics/covidresilience-ranking/. Accessed 11 October 2021\n-\n[Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-Jones R, Cutland CL, Darton TC, Dheda K, Duncan CJA, Emary KRW, Ewer KJ, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Goodman AL, Green CM, Green CA, Heath PT, Hill C, Hill H, Hirsch I, Hodgson SHC, Izu A, Jackson S, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Lawrie AM, Lelliott A, Libri V, Lillie PJ, Mallory R, Mendes AVA, Milan EP, Minassian AM, McGregor A, Morrison H, Mujadidi YF, Nana A, O'Reilly PJ, Padayachee SD, Pittella A, Plested E, Pollock KM, Ramasamy MN, Rhead S, Schwarzbold AV, Singh N, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Tarrant R, Thomson EC, Torok ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, Watson MEE, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8. Erratum In: Lancet. 2021 Jan 9;397(10269):98.](https://ichgcp.net/es/clinical-trials-registry/publications/24708-safety-and-efficacy-of-the-chadox1-ncov-19-vaccine-azd1222-against-sars-cov-2-an-interim-analysis-of)\n- Our world in Data. Downloaded from https://ourworldindata.org/covidvaccinations. Accessed 11 April 2022.\n- CNN. Downloaded from https://edition.cnn.com/2021/04/03/health/uscoronavirus-saturday/index.html. Accessed 11 October 2021.\n- World Health Organization. Downloaded from https://www.who.int/newsroom/feature-stories/detail/vaccine-efficacy-effectiveness-and-protection. Accessed 11 October 2021\n-\n[Palacios R, Patino EG, de Oliveira Piorelli R, Conde MTRP, Batista AP, Zeng G, Xin Q, Kallas EG, Flores J, Ockenhouse CF, Gast C. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Oct 15;21(1):853. doi: 10.1186/s13063-020-04775-4.](https://ichgcp.net/es/clinical-trials-registry/publications/141520-double-blind-randomized-placebo-controlled-phase-iii-clinical-trial-to-evaluate-the-efficacy-and)\n-\n[Tanriover MD, Doganay HL, Akova M, Guner HR, Azap A, Akhan S, Kose S, Erdinc FS, Akalin EH, Tabak OF, Pullukcu H, Batum O, Simsek Yavuz S, Turhan O, Yildirmak MT, Koksal I, Tasova Y, Korten V, Yilmaz G, Celen MK, Altin S, Celik I, Bayindir Y, Karaoglan I, Yilmaz A, Ozkul A, Gur H, Unal S; CoronaVac Study Group. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021 Jul 17;398(10296):213-222. doi: 10.1016/S0140-6736(21)01429-X. Epub 2021 Jul 8. Erratum In: Lancet. 2022 Jan 29;399(10323):436.](https://ichgcp.net/es/clinical-trials-registry/publications/101344-efficacy-and-safety-of-an-inactivated-whole-virion-sars-cov-2-vaccine-coronavac-interim-results-of-a)\n- Reuters. Downloaded from https://www.reuters.com/business/healthcarepharmaceuticals/indonesia-study-finds-chinas-sinovac-covid-19-vaccine-effectivemedical-staff-2021-05-12/. Accessed 11 October 2021\n-\n[Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, Al Nusair M, Hassany M, Jawad JS, Abdalla J, Hussein SE, Al Mazrouei SK, Al Karam M, Li X, Yang X, Wang W, Lai B, Chen W, Huang S, Wang Q, Yang T, Liu Y, Ma R, Hussain ZM, Khan T, Saifuddin Fasihuddin M, You W, Xie Z, Zhao Y, Jiang Z, Zhao G, Zhang Y, Mahmoud S, ElTantawy I, Xiao P, Koshy A, Zaher WA, Wang H, Duan K, Pan A, Yang X. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. JAMA. 2021 Jul 6;326(1):35-45. doi: 10.1001/jama.2021.8565.](https://ichgcp.net/es/clinical-trials-registry/publications/64750-effect-of-2-inactivated-sars-cov-2-vaccines-on-symptomatic-covid-19-infection-in-adults-a-randomized)\n-\n[Kyriakidis NC, Lopez-Cortes A, Gonzalez EV, Grimaldos AB, Prado EO. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines. 2021 Feb 22;6(1):28. doi: 10.1038/s41541-021-00292-w.](https://ichgcp.net/es/clinical-trials-registry/publications/128221-sars-cov-2-vaccines-strategies-a-comprehensive-review-of-phase-3-candidates)\n-\n[Mendonca SA, Lorincz R, Boucher P, Curiel DT. Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic. NPJ Vaccines. 2021 Aug 5;6(1):97. doi: 10.1038/s41541-021-00356-x.](https://ichgcp.net/es/clinical-trials-registry/publications/141521-adenoviral-vector-vaccine-platforms-in-the-sars-cov-2-pandemic)\n-\n[Yadav T, Srivastava N, Mishra G, Dhama K, Kumar S, Puri B, Saxena SK. Recombinant vaccines for COVID-19. Hum Vaccin Immunother. 2020 Dec 1;16(12):2905-2912. doi: 10.1080/21645515.2020.1820808. Epub 2020 Nov 24.](https://ichgcp.net/es/clinical-trials-registry/publications/141522-recombinant-vaccines-for-covid-19)\n-\n[Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol. 2021 Feb;21(2):83-100. doi: 10.1038/s41577-020-00479-7. Epub 2020 Dec 22. Erratum In: Nat Rev Immunol. 2021 Jan 5;:](https://ichgcp.net/es/clinical-trials-registry/publications/141523-a-guide-to-vaccinology-from-basic-principles-to-new-developments)\n-\n[Excler JL, Saville M, Berkley S, Kim JH. Vaccine development for emerging infectious diseases. Nat Med. 2021 Apr;27(4):591-600. doi: 10.1038/s41591-021-01301-0. Epub 2021 Apr 12.](https://pubmed.ncbi.nlm.nih.gov/33846611)\n-\n[Bhattacharya S, Dasgupta R. Smallpox and polio eradication in India: comparative histories and lessons for contemporary policy. Cien Saude Colet. 2011 Feb;16(2):433-44. doi: 10.1590/s1413-81232011000200007.](https://ichgcp.net/es/clinical-trials-registry/publications/141524-smallpox-and-polio-eradication-in-india-comparative-histories-and-lessons-for-contemporary-policy)\n- CNN Indonesia. Downloaded from https://www.cnnindonesia.com/ekonomi/20210615172504-92-654688/bio-farmayakin-ri-bisa-dapat-400-juta-dosis-vaksin-tahun-ini. Accessed 111 Ocotber 2021.\n- Suara.com. Downloaded from https://www.suara.com/bisnis/2020/11/06/151502/ini-6-lembaga-yangkembangkan-vaksin-merah-putih. Accessed 11 October 2021.\n- World Health Organization. Considerations of evaluation of Covid-19 vaccines. Revised. Version of 30 March 2022. Geneva: WHO, 2021\n- Wang K, Jia Z, Bao L, et al. A subset of Memory B-derived antibody repertoire from 3-dose vaccinees is ultrapotent against diverse and highly transmissible SARS-CoV-2 variants, including Omicron. BioRXiv 2021; doi: https://doi.org/10.1101/2021.12.24.474084;\n-\n[Jara A, Undurraga EA, Gonzalez C, Paredes F, Fontecilla T, Jara G, Pizarro A, Acevedo J, Leo K, Leon F, Sans C, Leighton P, Suarez P, Garcia-Escorza H, Araos R. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. N Engl J Med. 2021 Sep 2;385(10):875-884. doi: 10.1056/NEJMoa2107715. Epub 2021 Jul 7.](https://ichgcp.net/es/clinical-trials-registry/publications/141525-effectiveness-of-an-inactivated-sars-cov-2-vaccine-in-chile)\n-\n[Fonseca MHG, de Souza TFG, de Carvalho Araujo FM, de Andrade LOM. Dynamics of antibody response to CoronaVac vaccine. J Med Virol. 2022 May;94(5):2139-2148. doi: 10.1002/jmv.27604. Epub 2022 Jan 28.](https://ichgcp.net/es/clinical-trials-registry/publications/141526-dynamics-of-antibody-response-to-coronavac-vaccine)\n-\n[Mascellino MT, Di Timoteo F, De Angelis M, Oliva A. Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety. Infect Drug Resist. 2021 Aug 31;14:3459-3476. doi: 10.2147/IDR.S315727. eCollection 2021.](https://ichgcp.net/es/clinical-trials-registry/publications/141527-overview-of-the-main-anti-sars-cov-2-vaccines-mechanism-of-action-efficacy-and-safety)\n-\n[Prubeta BM. Current State of the First COVID-19 Vaccines. Vaccines (Basel). 2021 Jan 8;9(1):30. doi: 10.3390/vaccines9010030.](https://ichgcp.net/es/clinical-trials-registry/publications/141528-current-state-of-the-first-covid-19-vaccines)\n-\n[Mallapaty S. China's COVID vaccines have been crucial - now immunity is waning. Nature. 2021 Oct;598(7881):398-399. doi: 10.1038/d41586-021-02796-w. No abstract available.](https://pubmed.ncbi.nlm.nih.gov/34650240)\n-\n[Fadlyana E, Rusmil K, Tarigan R, Rahmadi AR, Prodjosoewojo S, Sofiatin Y, Khrisna CV, Sari RM, Setyaningsih L, Surachman F, Bachtiar NS, Sukandar H, Megantara I, Murad C, Pangesti KNA, Setiawaty V, Sudigdoadi S, Hu Y, Gao Q, Kartasasmita CB. A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia. Vaccine. 2021 Oct 22;39(44):6520-6528. doi: 10.1016/j.vaccine.2021.09.052. Epub 2021 Sep 24.](https://ichgcp.net/es/clinical-trials-registry/publications/141529-a-phase-iii-observer-blind-randomized-placebo-controlled-study-of-the-efficacy-safety-and)\n-\n[Dinc HO, Saltoglu N, Can G, Balkan II, Budak B, Ozbey D, Caglar B, Karaali R, Mete B, Tuyji Tok Y, Ersoy Y, Ahmet Kuskucu M, Midilli K, Ergin S, Kocazeybek BS. Inactive SARS-CoV-2 vaccine generates high antibody responses in healthcare workers with and without prior infection. Vaccine. 2022 Jan 3;40(1):52-58. doi: 10.1016/j.vaccine.2021.11.051. Epub 2021 Nov 22.](https://ichgcp.net/es/clinical-trials-registry/publications/141530-inactive-sars-cov-2-vaccine-generates-high-antibody-responses-in-healthcare-workers-with-and-without)\n-\n[Guzel EC, Celikkol A, Erdal B, Sedef N. Immunogenicity after CoronaVac vaccination. Rev Assoc Med Bras (1992). 2021 Oct;67(10):1403-1408. doi: 10.1590/1806-9282.20210389.](https://ichgcp.net/es/clinical-trials-registry/publications/141531-immunogenicity-after-coronavac-vaccination)\n- Palacios R, Batista AP, Albuquerque, et al. Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study. SSRN 2021\n-\n[Escobar A, Reyes-Lopez FE, Acevedo ML, Alonso-Palomares L, Valiente-Echeverria F, Soto-Rifo R, Portillo H, Gatica J, Flores I, Nova-Lamperti E, Barrera-Avalos C, Bono MR, Vargas L, Simon V, Leiva-Salcedo E, Vial C, Hormazabal J, Cortes LJ, Valdes D, Sandino AM, Imarai M, Acuna-Castillo C. Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group. Front Immunol. 2022 Jan 31;12:766278. doi: 10.3389/fimmu.2021.766278. eCollection 2021.](https://ichgcp.net/es/clinical-trials-registry/publications/141532-evaluation-of-the-immune-response-induced-by-coronavac-28-day-schedule-vaccination-in-a-healthy)\n-\n[Hitchings MDT, Ranzani OT, Torres MSS, de Oliveira SB, Almiron M, Said R, Borg R, Schulz WL, de Oliveira RD, da Silva PV, de Castro DB, Sampaio VS, de Albuquerque BC, Ramos TCA, Fraxe SHH, da Costa CF, Naveca FG, Siqueira AM, de Araujo WN, Andrews JR, Cummings DAT, Ko AI, Croda J. Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study. Lancet Reg Health Am. 2021 Sep;1:100025. doi: 10.1016/j.lana.2021.100025. Epub 2021 Jul 25.](https://ichgcp.net/es/clinical-trials-registry/publications/141533-effectiveness-of-coronavac-among-healthcare-workers-in-the-setting-of-high-sars-cov-2-gamma-variant)\n- De Faria E, Guedes AR, Oliveira MS, et al. Performance of vaccination with CoronaVac in a cohort of healthcare workers (HCW) - preliminary report. MedRXiv 2021; https://doi.org/10.1101/2021.04.12.21255308\n-\n[Ranzani OT, Hitchings MDT, Dorion M, D'Agostini TL, de Paula RC, de Paula OFP, Villela EFM, Torres MSS, de Oliveira SB, Schulz W, Almiron M, Said R, de Oliveira RD, Vieira da Silva P, de Araujo WN, Gorinchteyn JC, Andrews JR, Cummings DAT, Ko AI, Croda J. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study. BMJ. 2021 Aug 20;374:n2015. doi: 10.1136/bmj.n2015. Erratum In: BMJ. 2021 Sep 6;374:n2091.](https://ichgcp.net/es/clinical-trials-registry/publications/141534-effectiveness-of-the-coronavac-vaccine-in-older-adults-during-a-gamma-variant-associated-epidemic-of)\n- Soto JA, Melo-Gozales F, Gutierrez-Vera C, et al. An inactivated SARS-CoV-2 vaccine is safe and induces humoral and cellular immunity against virus variants in healthy children and adolescents in Chile. MedRXiv 2021; https://doi.org/10.1101/2022.02.15.22270973;\n- Schultz BM, Melo-Gonzales, Duarte LF, et al. A booster dose of an inactivated SARS-1 CoV-2 vaccine increases neutralizing antibodies and T cells that recognize Delta and Omicron variants of concern. MedRXiv 2021; https://doi.org/10.1101/2021.11.16.21266350\n- Joko Widodo gets first Sinovac vaccine shot as Indonesia starts mass Covid-19 inoculations. South China Morning Post. Accessed 3 June 2022. Downloaded at: https://www.scmp.com/video/coronavirus/3117548/joko-widodo-gets-first-sinovacvaccine-shot-indonesia-starts-mass-covid\n-\n[Peng Q, Zhou R, Wang Y, Zhao M, Liu N, Li S, Huang H, Yang D, Au KK, Wang H, Man K, Yuen KY, Chen Z. Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong. EBioMedicine. 2022 Mar;77:103904. doi: 10.1016/j.ebiom.2022.103904. Epub 2022 Mar 3.](https://ichgcp.net/es/clinical-trials-registry/publications/141535-waning-immune-responses-against-sars-cov-2-variants-of-concern-among-vaccinees-in-hong-kong)\nFechas de registro del estudio\nFechas importantes del estudio\nInicio del estudio (ACTUAL)\nFinalizaci\u00f3n primaria (ANTICIPADO)\nFinalizaci\u00f3n del estudio (ANTICIPADO)\nFechas de registro del estudio\nEnviado por primera vez\nPrimero enviado que cumpli\u00f3 con los criterios de control de calidad\nPublicado por primera vez (ACTUAL)\nActualizaciones de registros de estudio\n\u00daltima actualizaci\u00f3n publicada (ACTUAL)\n\u00daltima actualizaci\u00f3n enviada que cumpli\u00f3 con los criterios de control de calidad\n\u00daltima verificaci\u00f3n\nM\u00e1s informaci\u00f3n\nT\u00e9rminos relacionados con este estudio\nPalabras clave\nT\u00e9rminos MeSH relevantes adicionales\nOtros n\u00fameros de identificaci\u00f3n del estudio\n- UNAIR-MP-INAKTIF-III-01\nPlan de datos de participantes individuales (IPD)\n\u00bfPlanea compartir datos de participantes individuales (IPD)?\nInformaci\u00f3n sobre medicamentos y dispositivos, documentos del estudio\nEstudia un producto farmac\u00e9utico regulado por la FDA de EE. UU.\nEstudia un producto de dispositivo regulado por la FDA de EE. UU.\nEsta informaci\u00f3n se obtuvo directamente del sitio web\n[clinicaltrials.gov](https://clinicaltrials.gov) sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comun\u00edquese con [register@clinicaltrials.gov](mailto:register@clinicaltrials.gov). Tan pronto como se implemente un cambio en [clinicaltrials.gov](https://clinicaltrials.gov), tambi\u00e9n se actualizar\u00e1 autom\u00e1ticamente en nuestro sitio web. .\nEnsayos cl\u00ednicos sobre Pandemia de COVID-19\n-\nNCT06036134A\u00fan no reclutandoSalud Conocimiento, Actitudes, Pr\u00e1ctica | Pandemia de COVID-19 | Enfermedades prevenibles por vacunaci\u00f3n | Comportamiento relacionado con la salud | Narraci\u00f3n\n-\nNCT06036251A\u00fan no reclutandoEstr\u00e9s | Estr\u00e9s, Emocional | Pandemia de COVID-19 | Reacci\u00f3n de estr\u00e9s\n-\nNCT05923398ReclutamientoAngustia, Emocional | Reacci\u00f3n de estr\u00e9s; Agudo | Respuesta al Estr\u00e9s de los Profesionales de Enfermer\u00eda Durante el COVID-19\n-\nNCT05918939ReclutamientoPandemia de COVID-19 | Vacunas para COVID-19\n-\nNCT05908045A\u00fan no reclutando\n-\nNCT05894655A\u00fan no reclutando\n[Optimizaci\u00f3n participada por la comunidad de las experiencias de prueba y evaluaci\u00f3n r\u00e1pida de COVID-19 (CO-CREATE-Ex)](https://ichgcp.net/es/clinical-trials-registry/NCT05894655)COVID-19 | Pandemia de COVID-19\n-\nNCT05855421ReclutamientoDepresi\u00f3n | Calidad de vida | Insomnio | Ansiedad | Sintomas depresivos\n-\nNCT05851807Reclutamiento\n[Mec\u00e1nica pulmonar intraoperatoria, complicaciones posoperatorias y evaluaci\u00f3n funcional en pacientes post-COVID sometidos a cirug\u00eda tor\u00e1cica](https://ichgcp.net/es/clinical-trials-registry/NCT05851807)Anestesia | Enfermedades tor\u00e1cicas | Pandemia de COVID-19\n-\nNCT05825651ReclutamientoReinfecci\u00f3n | Reacci\u00f3n a la vacuna | COVID largo | Pandemia de COVID-19 | Infecci\u00f3n de ancianos | Factores de estilo de vida\n-\nNCT05770362A\u00fan no reclutando\n[Cambios en el estilo de vida por la pandemia de COVID-19 en ni\u00f1os con retrasos en el desarrollo (COVID-19)](https://ichgcp.net/es/clinical-trials-registry/NCT05770362)Pandemia de COVID-19 | Condici\u00f3n relacionada con el estilo de vida | Ni\u00f1os con retrasos en el desarrollo\nEnsayos cl\u00ednicos sobre Vaksin Merah Putih - UA SARS-CoV-2 (c\u00e9lulas Vero inactivadas) 5 \u00b5g\n-\nNCT05918939ReclutamientoPandemia de COVID-19 | Vacunas para COVID-19", "language": null, "image": null, "pagetype": "website", "links": ["https://ichgcp.net/es", "#", "https://ichgcp.net/de", "https://ichgcp.net/", "https://ichgcp.net/es", "https://ichgcp.net/fr", "https://ichgcp.net/it", "https://ichgcp.net/pt", "https://ichgcp.net/ru", "https://ichgcp.net/es/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects", "https://ichgcp.net/es/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol", "https://ichgcp.net/es/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia", "https://ichgcp.net/es/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan", "https://ichgcp.net/es/ich-e-group-of-guidelines", "https://ichgcp.net/es/cro-list", "https://ichgcp.net/es/clinical-trials-registry", "https://ichgcp.net/es/eu-clinical-trials-registry", "https://ichgcp.net/es/pharma-list", "https://ichgcp.net/es/labs", "https://ichgcp.net/es/service-companies", "https://ichgcp.net/es/events", "https://ichgcp.net/es/clinical-trials-registry/publications", "https://ichgcp.net/es/clinical-trials-registry/researchers", "https://ichgcp.net/es/cra-jobs", "https://ichgcp.net/es/publications", "https://ichgcp.net/es/news", "https://ichgcp.net/clinical-trials-registry/NCT05508477", "https://telegram.me/share/url?url=https://ichgcp.net/es/clinical-trials-registry/NCT05508477&text=", "https://twitter.com/intent/tweet?url=https://ichgcp.net/es/clinical-trials-registry/NCT05508477", "https://ichgcp.net/es", "https://ichgcp.net/es/clinical-trials-registry", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Dr.%20Soetomo%20General%20Hospital", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=COVID-19%20Pandemic", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=COVID-19%20Vaccines", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Vaksin%20Merah%20Putih%20-%20UA%20SARS-CoV-2%20%28Vero%20Cell%20Inactivated%29%205%20%C2%B5g", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=CoronaVac%20Biofarma%20COVID-19%20Vaccine", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Vaksin%20Merah%20Putih%20-%20UA%20SARS-CoV-2%20%28Vero%20Cell%20Inactivated%29%205%20%C2%B5g", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=CoronaVac%20Biofarma%20COVID-19%20Vaccine", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Dr.%20Soetomo%20General%20Hospital", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Indonesia-MoH", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Universitas%20Airlangga", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Biotis%20Pharmaceuticals%2C%20Indonesia", "https://ichgcp.net/es/clinical-trials-registry/publications/5604-efficacy-and-safety-of-the-mrna-1273-sars-cov-2-vaccine", "https://ichgcp.net/es/clinical-trials-registry/publications/5603-safety-and-efficacy-of-the-bnt162b2-mrna-covid-19-vaccine", "https://ichgcp.net/es/clinical-trials-registry/publications/141516-covid-19-in-early-2021-current-status-and-looking-forward", "https://ichgcp.net/es/clinical-trials-registry/publications/141517-safe-hospital-preparedness-in-the-era-of-covid-19-the-swiss-cheese-model", "https://pubmed.ncbi.nlm.nih.gov/33767468", "https://ichgcp.net/es/clinical-trials-registry/publications/141518-reserving-coronavirus-disease-2019-vaccines-for-global-access-cross-sectional-analysis", "https://ichgcp.net/es/clinical-trials-registry/publications/141519-association-of-sex-age-and-comorbidities-with-mortality-in-covid-19-patients-a-systematic-review-and", "https://ichgcp.net/es/clinical-trials-registry/publications/24708-safety-and-efficacy-of-the-chadox1-ncov-19-vaccine-azd1222-against-sars-cov-2-an-interim-analysis-of", "https://ichgcp.net/es/clinical-trials-registry/publications/141520-double-blind-randomized-placebo-controlled-phase-iii-clinical-trial-to-evaluate-the-efficacy-and", "https://ichgcp.net/es/clinical-trials-registry/publications/101344-efficacy-and-safety-of-an-inactivated-whole-virion-sars-cov-2-vaccine-coronavac-interim-results-of-a", "https://ichgcp.net/es/clinical-trials-registry/publications/64750-effect-of-2-inactivated-sars-cov-2-vaccines-on-symptomatic-covid-19-infection-in-adults-a-randomized", "https://ichgcp.net/es/clinical-trials-registry/publications/128221-sars-cov-2-vaccines-strategies-a-comprehensive-review-of-phase-3-candidates", "https://ichgcp.net/es/clinical-trials-registry/publications/141521-adenoviral-vector-vaccine-platforms-in-the-sars-cov-2-pandemic", "https://ichgcp.net/es/clinical-trials-registry/publications/141522-recombinant-vaccines-for-covid-19", "https://ichgcp.net/es/clinical-trials-registry/publications/141523-a-guide-to-vaccinology-from-basic-principles-to-new-developments", "https://pubmed.ncbi.nlm.nih.gov/33846611", "https://ichgcp.net/es/clinical-trials-registry/publications/141524-smallpox-and-polio-eradication-in-india-comparative-histories-and-lessons-for-contemporary-policy", "https://ichgcp.net/es/clinical-trials-registry/publications/141525-effectiveness-of-an-inactivated-sars-cov-2-vaccine-in-chile", "https://ichgcp.net/es/clinical-trials-registry/publications/141526-dynamics-of-antibody-response-to-coronavac-vaccine", "https://ichgcp.net/es/clinical-trials-registry/publications/141527-overview-of-the-main-anti-sars-cov-2-vaccines-mechanism-of-action-efficacy-and-safety", "https://ichgcp.net/es/clinical-trials-registry/publications/141528-current-state-of-the-first-covid-19-vaccines", "https://pubmed.ncbi.nlm.nih.gov/34650240", "https://ichgcp.net/es/clinical-trials-registry/publications/141529-a-phase-iii-observer-blind-randomized-placebo-controlled-study-of-the-efficacy-safety-and", "https://ichgcp.net/es/clinical-trials-registry/publications/141530-inactive-sars-cov-2-vaccine-generates-high-antibody-responses-in-healthcare-workers-with-and-without", "https://ichgcp.net/es/clinical-trials-registry/publications/141531-immunogenicity-after-coronavac-vaccination", "https://ichgcp.net/es/clinical-trials-registry/publications/141532-evaluation-of-the-immune-response-induced-by-coronavac-28-day-schedule-vaccination-in-a-healthy", "https://ichgcp.net/es/clinical-trials-registry/publications/141533-effectiveness-of-coronavac-among-healthcare-workers-in-the-setting-of-high-sars-cov-2-gamma-variant", "https://ichgcp.net/es/clinical-trials-registry/publications/141534-effectiveness-of-the-coronavac-vaccine-in-older-adults-during-a-gamma-variant-associated-epidemic-of", "https://ichgcp.net/es/clinical-trials-registry/publications/141535-waning-immune-responses-against-sars-cov-2-variants-of-concern-among-vaccinees-in-hong-kong", "https://ichgcp.net/es/clinical-trials-registry/research/list?term=Safety", "https://ichgcp.net/es/clinical-trials-registry/research/list?term=COVID-19", "https://ichgcp.net/es/clinical-trials-registry/research/list?term=Immunogenicity", "https://ichgcp.net/es/clinical-trials-registry/research/list?term=Indonesia", "https://ichgcp.net/es/clinical-trials-registry/research/list?term=Inactivated%20COVID-19%20Vaccine", "https://ichgcp.net/es/clinical-trials-registry/research/list?term=Immunobridging%20study", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Coronavirus%20Infections", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Coronaviridae%20Infections", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Nidovirales%20Infections", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=RNA%20Virus%20Infections", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Virus%20Diseases", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Infections", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Respiratory%20Tract%20Infections", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Respiratory%20Tract%20Diseases", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Pneumonia%2C%20Viral", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Pneumonia", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Lung%20Diseases", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=COVID-19", "https://clinicaltrials.gov", "mailto:register@clinicaltrials.gov", "https://clinicaltrials.gov", "https://ichgcp.net/es/clinical-trials-registry/NCT06036134", "https://ichgcp.net/es/clinical-trials-registry/NCT06036251", "https://ichgcp.net/es/clinical-trials-registry/NCT05923398", "https://ichgcp.net/es/clinical-trials-registry/NCT05918939", "https://ichgcp.net/es/clinical-trials-registry/NCT05908045", "https://ichgcp.net/es/clinical-trials-registry/NCT05894655", "https://ichgcp.net/es/clinical-trials-registry/NCT05855421", "https://ichgcp.net/es/clinical-trials-registry/NCT05851807", "https://ichgcp.net/es/clinical-trials-registry/NCT05825651", "https://ichgcp.net/es/clinical-trials-registry/NCT05770362", "https://ichgcp.net/es/clinical-trials-registry/NCT05918939", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Jos%25C3%25A9phine%2BSOLTANI%252C%2BCardiology%2Bdepartment%252C%2BVersailles%2BHospital", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Cairo%2BUniversity", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Pfizer", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Universidade%2Bde%2BLisboa%252C%2BPortugal", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Center%2Bfor%2BIndustrial%2BTechnological%2BDevelopment%2Bof%2BSpain", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Pediatric%2BOrthopaedic%2BSociety%2Bof%2BNorth%2BAmerica", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=GlaxoSmithKline", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Universidad%2Bdel%2BZulia", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=SeeCure%2BLLC", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=AstraZeneca", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Assiut%2BUniversity", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=European%2BSociety%2Bof%2BHuman%2BReproduction%2Band%2BEmbryology", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=M.D.%2BAnderson%2BCancer%2BCenter", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Mayo%2BClinic", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Assistance%2BPublique%2B-%2BH%25C3%25B4pitaux%2Bde%2BParis", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Medtronic%2BSurgical%2BTechnologies", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Kaneka%2BAmericas%2BHolding%2BInc.", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Novartis%2BPharmaceuticals", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=National%2BCancer%2BInstitute%2B%2528NCI%2529", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Orphanetics%2BPharma%2BEntwicklungs%2BGmbH", "https://ichgcp.net/es/clinical-trials-registry/research/browse/spns_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Stage%2BI%2BGallbladder%2BCancer%2BAJCC%2Bv8", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Carcinoma%252C%2BAdrenal%2BCortical", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Ankle%2BArthroplasty", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Post-traumatic%2BAnosmia", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Esophageal%2BResection%2BCandidates", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Obesity", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Postneoadjuvant%2BTherapy%2BStage%2BI%2BGastric%2BCancer%2BAJCC%2Bv8", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Coronary%2BArtery%2BDisease", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Malignant%2BNeoplasm%2Bof%2BRespiratory%2Band%2BIntrathoracic%2BOrgan%2BCarcinoma", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Pain", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Breast%2BCancer", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Prostate%2BCancer", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Colon%2BMalignant%2BTumor", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Asthma", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Depression", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Hypertension", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Cushing%2527s%2BSyndrome%2BI", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=HIV%2BInfections", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Ultrasound%2BEvaluation", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Stroke", "https://ichgcp.net/es/clinical-trials-registry/research/browse/cond_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Capecitabine", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Injectafer", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=MK-8521%2B100%25CE%25BCg", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cisplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Carboplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Pilocarpine%2B1.25%2525%2BEye%2Bdrop", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Gemcitabine", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cyclophosphamide", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Teicoplanin%2BSandoz%2B200%2Bmg%2Bpowder%2Band%2Bsolvent%2Bfor%2Bsolution%2Bfor%2Binjection%2Bor%2Binfusion%2Bor%2Boral%2Bsolution.", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Brimonidine%2Btartrate%2Bophthalmic%2Bsolution%2B0.025%2525%2B%2528n%2B%253D%2B56%2529", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Valacyclovir%2Barrow", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Docetaxel", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Prednisone", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Bevacizumab", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Oral%2BGlucose%2BGel", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Alpelisib%2B150%2BMG%2BOral%2BTablet%2B%255BPiqray%255D", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Paclitaxel", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Transplant%2B2%2BMelphalan", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=20mg%2BAzilsartan%2BTablets", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Dexamethasone", "https://ichgcp.net/es/clinical-trials-registry/research/browse/intr_alpha_all", "https://ichgcp.net/es/cro-list/country/benin", "https://ichgcp.net/es/cro-list/country/costa_rica", "https://ichgcp.net/es/cro-list/country/croatia", "https://ichgcp.net/es/cro-list/country/cyprus", "https://ichgcp.net/es/cro-list/country/egypt", "https://ichgcp.net/es/cro-list/country/kazakhstan", "https://ichgcp.net/es/cro-list/country/luxembourg", "https://ichgcp.net/es/cro-list/country/netherlands", "https://ichgcp.net/es/cro-list/country/paraguay", "https://ichgcp.net/es/cro-list/country/peru", "https://ichgcp.net/es/cro-list/country/philippines", "https://ichgcp.net/es/cro-list/country/thailand", "https://ichgcp.net/es/cro-list/country/zimbabwe", "https://ichgcp.net/es/cro-list", "https://ichgcp.net/es/cro-list/country/south_africa/company/labcorp_drug_development", "https://ichgcp.net/es/cro-list/country/south_africa/company/andurihl_medical_writing_cc", "https://ichgcp.net/es/cro-list/country/south_africa/company/fhi_clinical", "https://ichgcp.net/es/cro-list/country/south_africa/company/ppd", "https://ichgcp.net/es/cro-list/country/south_africa/company/key_oncologics_pty_ltd", "https://ichgcp.net/es/cro-list/country/south_africa/company/pra_health_sciences", "https://ichgcp.net/es/cro-list/country/south_africa/company/siri_technologies", "https://ichgcp.net/es/cro-list/country/south_africa/company/celero", "https://ichgcp.net/es/cro-list/country/south_africa/company/parexel", "https://ichgcp.net/es/cro-list/country/south_africa/company/medpace", "https://ichgcp.net/es/cro-list/country/south_africa", "https://ichgcp.net/es/clinical-trials-registry/research/browse/cond_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/cond_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/ord_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/intr_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/intr_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/diet_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/diet_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/spns_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/spns_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/locn_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/locn_cat", "https://ichgcp.net/es", "https://ichgcp.net/es/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects", "https://ichgcp.net/es/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol", "https://ichgcp.net/es/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia", "https://ichgcp.net/es/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan", "https://ichgcp.net/es/guideline-for-the-notification-of-serious-breaches-of-regulation-eu-no-536-2014", "https://ichgcp.net/es/cro-list", "https://ichgcp.net/es/pharma-list", "https://ichgcp.net/es/labs", "https://ichgcp.net/es/service-companies", "https://ichgcp.net/es/cra-jobs", "https://ichgcp.net/es/clinical-trials-registry", "https://ichgcp.net/es/eu-clinical-trials-registry", "https://ichgcp.net/es/publications", "https://ichgcp.net/es/news", "https://ichgcp.net/about-us-our-mission", "https://ichgcp.net/es/sitemap", "https://ichgcp.net/es/contact-us", "https://ichgcp.net/es/feed", "/privacy", "/disclaimer", "https://ichgcp.net/da/clinical-trials-registry/NCT05508477", "https://ichgcp.net/de/clinical-trials-registry/NCT05508477", "https://ichgcp.net/clinical-trials-registry/NCT05508477", "https://ichgcp.net/es/clinical-trials-registry/NCT05508477", "https://ichgcp.net/fr/clinical-trials-registry/NCT05508477", "https://ichgcp.net/it/clinical-trials-registry/NCT05508477", "https://ichgcp.net/hu/clinical-trials-registry/NCT05508477", "https://ichgcp.net/nl/clinical-trials-registry/NCT05508477", "https://ichgcp.net/no/clinical-trials-registry/NCT05508477", "https://ichgcp.net/pl/clinical-trials-registry/NCT05508477", "https://ichgcp.net/pt/clinical-trials-registry/NCT05508477", "https://ichgcp.net/fi/clinical-trials-registry/NCT05508477", "https://ichgcp.net/sv/clinical-trials-registry/NCT05508477", "https://ichgcp.net/cs/clinical-trials-registry/NCT05508477", "https://ichgcp.net/ru/clinical-trials-registry/NCT05508477", "https://ichgcp.net/ja/clinical-trials-registry/NCT05508477", "https://ichgcp.net/zh/clinical-trials-registry/NCT05508477", "https://ichgcp.net/ko/clinical-trials-registry/NCT05508477", "https://ichgcp.net/pdf/privacy_cookies_policy.pdf", "https://ichgcp.net/pdf/terms_of_service.pdf", "https://ichgcp.net/pdf/privacy_cookies_policy.pdf", "https://ichgcp.net/pdf/terms_of_service.pdf"]}